Acquisition to deliver significant progress in manufacturing and technology capabilities, and will further propel CRISPR QC's success in the fast growing gene editing market.
Cell therapy and oncology drug development expert aims to lead Senti Bio's novel off-the-shelf CAR-NK cell oncology programs into and through clinical development
Source: Senti Biosciences, Inc.
